Biomarker Solutions

The BioCog App was recently successfully presented in the European Institute of Innovation and Technology’s Health Wildcard competition. This success will greatly facilitate our efforts to enter the market with our App within the next two years. The BioCog App will allow the prediction of cognitive impairments after surgical interventions in the elderly. This will be of enormous potential benefit for patients, health care providers and health insurance carriers.

Learn more: World-first test to reduce post-surgery risks to brain health

Pharmaimage Biomarker Solutions Inc. BostonBerlin - Boston: We are pleased to announce that Pharmaimage has opened an additional location in Boston/USA.

Serious adverse events (SAEs) during clinical phase-I studies (first dosing, dose escalation) are rare but can be devastating as exemplified by the recent incident at the clinical research organization (CRO) Biotrial in France or another incident during a trial that was conducted by the CRO Parexel (UK) in 2006.

Pharmaimage (Berlin, Germany) and the Clinical Research Organization (CRO) Hammersmith Medicines Research (HMR) in London (UK) have established a real-time neurophysiological/video monitoring system as part of a new phase-I drug trial.

The FP7 EU-funded BioCog Consortium (Biomarker Development for Postoperative Cognitive Impairment in the Elderly), which includes Pharmaimage GmbH as a major partner, has been selected by the Berlin Institute of Health (BIH) as a „pathfinder study“.

Pharmaimage is happy to announce its participation as a strategic partner of the newly established EU-funded FP7 research consortium: Biomarker Development for Postoperative Cognitive Impairment in the Elderly (BioCog):

© PI-PharmaImage Germany GmbH 2017 | Webdesign: blickpunkt x, Köln

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.